This editorial refers to 'Correlations between MTHFR gene polymorphisms and venous thromboembolism: a meta-analysis of 99 genetic association studies'.
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Deep vein thrombosis (DVT) is a major preventable cause of morbidity and mortality worldwide. 2 Thrombophilia is considered to be a condition predisposing to the development of thrombosis. 3 Venous thromboembolism (VTE) is the most common vascular disease after acute myocardial infarction and stroke. 3 Although VTE is a common disease, the underlying pathogenic mechanisms are only partially known, particularly in comparison to atherothrombosis. Over the years, progress has been made in the identification and characterisation of the cellular and molecular mechanisms. It is now accepted that the combination of stasis and hypercoagulability, much more than endothelial damage, is crucial for the occurrence of VTE; venous thrombi are mainly constituted by fibrin and red blood cells and less by platelets. 3 There are myriad risk factors for VTE, such as age, metabolic syndrome, hypercoagulability, oncological surgery and others, but what about the association of gene polymorphism with its development? Why was it not included in classic risk factors?
At the same time, there are many studies about the relationship between methylenetetrahydrofolate reductase (MTHFR) and different diseases from oncological to cardiovascular. According to PubMed, most of these studies have taken place in Asia. [4] [5] [6] [7] What is known is that MTHFR is an enzyme that catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methytetrahydrofolate, the carbon donor for the remethylation of homocysteine to methionine. 6 In addition, the MTHFR C677T and A1298C polymorphisms, as common genetic causes for hyperhomocysteinemia, are also expected to be associated with hypertension and hypertension in pregnancy. 5, 6 Moreover, the distribution of the MTHFR A1298C polymorphism is not as well studied as that of C677T. Interestingly, in contrast to the distribution of C677T, the prevalence of the 1298C allele and the 1298CC genotype has shown a decreasing trend from southern to northern China. 5 As a matter of fact, the MTHFR A1298C polymorphism has been found all over the world, with the greatest amount of it in Asian countries. 5 In 2016, Wang et al. 7 clarified that there are significant geographical and ethnic variations in the frequencies of the C677T, A1298C and A66G gene polymorphisms in the folate metabolism pathway among the Chinese population. At the same time, Raina et al. found a significant association of both the MTHFR (C677T) and MTR (A2756G) gene polymorphisms with cardiovascular diseases. 4 Multiple epidemiological studies have demonstrated that homocysteine is an important biomarker with biological functions in the folate metabolism pathway. Hyperhomocysteinemia is a medical health problem characterised by elevated homocysteine concentrations, 7 and it was mentioned as a well-established risk factor for thrombosis by J. Zeng and also Q. Zeng. As a result, functional genetic variations of MTHFR, which may lead to disruption of homocysteine metabolism and result in hyperhomocysteinemia, were thought to be implicated in the development of thrombotic disorders such as VTE.
The study by Zeng and Zeng 1 demonstrates that the MTHFR rs18001133 polymorphism may serve as a potential biological marker for VTE in Caucasians, East Asians and West Asians. The authors postulate that the MTHFR rs18001133 polymorphism may be implicated in the development of deep vein thrombosis and pulmonary embolism. In fact, Kesieme et al. have discussed the genetic risk factors for thrombosis development, such as fibrinogen, factor XIII, factor XI Nacional'nyj medicinskij issledovatel'skij centr imeni V A Almazova, Russian Federation, Russia variants, factor V Leiden, non-O blood group, deficiencies of anti-thrombin, protein C and protein S. 8 However, in their study there was a lack of information about gene polymorphism. J. Zeng and G. Zeng confirmed previous findings that the pathogenic mechanism of VTE is highly complex, and hence it is unlikely that a single MTHFR gene polymorphism can significantly contribute to its development.
The present study by Zeng and Zeng 1 points to an issue that individuals carrying the mutant allele of rs1801131 and rs1801133 polymorphisms were thought to be more prone to develop hyperhomocysteinemia and associated thrombotic disorders, which might help to develop novel therapeutic approaches for thrombosis and study how to prevent it. Their results may lead to the inclusion in a protocol checking for gene polymorphisms in high-risk patients for thrombosis.
Overall, there is an unmet need for novel therapeutic approaches that specifically target gene polymorphisms as an underestimated risk of thrombosis. The fact that a substantial number of individuals with classic risk factors such as trauma/fracture, pregnancy and oral contraception did not eventually develop VTE suggests that genetic predisposition may also play a crucial role in its occurrence and development. Like all meta-analyses, the study by Zeng and Zeng 1 certainly has some limitations. Due to a lack of original data, their results were just based on unadjusted estimations, and there was a failure to perform adjusted analyses for age, gender and comorbid conditions. Thus, the future approaches are not only examining patients with a risk of thrombosis for MTHFR gene polymorphisms, but also analysing their age, gender and other factors. As well as such polymorphisms being found all over the world, future studies in this field can turn into changing classic risk factors.
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